ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

Date : September 04, 2017

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care test for measuring active neutrophil elastase, and has successfully registered the product with a CE Mark. This allows the company to sell the product throughout Europe.

NEATstik® is a first-in-class diagnostic tool for the monitoring of lung inflammation and infection in patients with respiratory diseases such as COPD and bronchiectasis. COPD is known to affect in excess of 24 million patients in Europe alone. NEATstik® utilises the company’s proprietary ProteaseTag® technology, which permits specific and sensitive capture of only the active form of neutrophil elastase, and complements the laboratory-based Active NE Immunoassay, which was registered with a CE Mark in 2016.

Dr David Ribeiro, CEO of ProAxsis, said, “The point-of-care market was valued at $23.5 billion in 2016 and is expected to reach approximately $40.5 billion by 2022. We are very grateful, both to our excellent development partners, and to the investors and other innovation funders who have supported this extensive development programme. The CE Mark registration of NEATstik® represents the most significant milestone achievement to date for ProAxsis.”

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact